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Abstract
Background:  The plasma membrane neurotransmitter transporters terminate
neurotransmissions by the reuptake of the released neurotransmitters. The transporters for the
monoamines dopamine, norepinephrine, and serotonin (DAT, NET, and SERT) are targets for
several popular psychostimulant drugs of abuse. The potencies of the psychostimulant on the
monoamine transporters have been studied by several laboratories. However, there are significant
discrepancies in the reported data with differences up to 60-fold. In addition, the drug potencies of
the 3 monoamine transporters from mouse have not been compared in the same experiments or
along side the human transporters. Further studies and systematic comparisons are needed.
Results: In this study, we compared the potencies of five psychostimulant drugs to inhibit human
and mouse DAT, SERT and NET in the same cellular background. The KI values of cocaine to inhibit
the 3 transporters are within a narrow range of 0.2 to 0.7 µM. In comparison, methylphenidate
inhibited DAT and NET at around 0.1 µM, while it inhibited SERT at around 100 µM. The order of
amphetamine potencies was NET (KI = 0.07–0.1 µM), DAT (KI ≈ 0.6 µM), and SERT (KI between
20 to 40 µM). The results for methamphetamine were similar to those for amphetamine. In
contrast, another amphetamine derivative, MDMA (3–4 methylenedioxymethamphetamine),
exhibited higher potency at SERT than at DAT. The human and mouse transporters were similar
in their sensitivities to each of the tested drugs (KI values are within 4-fold).
Conclusion: The current and previous studies support the following conclusions: 1) cocaine
blocks all 3 monoamine transporters at similar concentrations; 2) methylphenidate inhibits DAT
and NET well but a 1000-fold higher concentration of the drug is required to inhibit SERT; 3)
Amphetamine and methamphetamine are most potent at NET, while being 5- to 9-fold less potent
at DAT, and 200- to 500-fold less potent at SERT; 4) MDMA has moderately higher apparent affinity
for SERT and NET than for DAT. The relative potencies of a drug to inhibit DAT, NET and SERT
suggest which neurotransmitter systems are disrupted the most by each of these stimulants and
thus the likely primary mechanism of drug action.
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Background
Drug abuse is a serious problem in the United States and
around the world that places tremendous social and eco-
nomical burdens on individuals and on the whole society
[1]. Psychostimulants are a group of drugs that stimulate
the activity of the central nervous system and produce a
series of effects in humans, such as increasing heart rate
and respiration, improving alertness, elevating mood and
self-confidence, and producing euphoria [2]. Common
psychostimulant drugs include: cocaine, methylphenidate
(Ritalin), amphetamine, methamphetamine, and MDMA
[2]. Some of these psychostimulants are useful medica-
tions that have long been used for treating various disor-
ders such as attention deficit hyperactivity disorder
(ADHD), narcolepsy, and obesity, while they are also
addictive substances that could cause serious adverse
effects when abused [2]. Psychostimulant abuse is a major
public health problem in the United States. According to
the 2003 National Survey on Drug Use and Health [3],
cocaine and amphetamine are two of the most abused
drugs while methamphetamine abuse has become a grow-
ing concern and 12.3 million Americans age twelve and
older had tried methamphetamine at least once in their
lifetimes. Methylphenidate is commonly prescribed as
Ritalin to treat ADHD. As the number of Ritalin prescrip-
tion increases, drug and law enforcement agencies are see-
ing an increase in Ritalin drug dealing and the illicit use of
Ritalin as a recreational drug [3]. The abuse of MDMA,
also known as Ecstasy, has also spread to a wide range of
settings and demographic subgroups and more than 10
million people have tried MDMA at least once [3].
Plasma membrane neurotransmitter transporters termi-
nate neurotransmissions by the reuptake and recycling of
the released neurotransmitters [4,5]. The transporters for
the monoamines dopamine, norepinephrine, and serot-
onin (DAT, NET, and SERT) belong to a family of Na+/Cl-
-dependent neurotransmitter transporters, which are
intrinsic membrane proteins containing 12 putative trans-
membrane domains [6,7]. Psychostimulants, such as
cocaine, methylphenidate, and amphetamine related
compounds interrupt the reuptake process by DAT, NET
and SERT [8-11]. Consequently, neurotransmissions are
prolonged and the extracellular concentrations of these
amine transmitters are elevated, resulting in complex neu-
rochemical changes and profound psychiatric effects [12].
In order to understand the effects of these psychostimu-
lant drugs, it is critical to determine which transporter or
neurotransmitter systems are most affected at low,
medium, or high drug doses. A thorough understanding
of the pharmacological profile for each psychostimulant
drug would be helpful for the development of treatment
protocols for stimulant overdose and dependence.
The potencies of different psychostimulant drugs at the
monoamine transporters have been studied and reported
by different laboratories [9,10,13-15]. However, there are
significant discrepancies among the reported data and the
differences are up to 60-fold. For instance, the inhibition
constant (KI) for amphetamine to inhibit DA uptake in rat
synaptosomes was reported to be 0.034 µM in one study
[16], while it was reported to be 2.3 µM in cultured cells
expressing rat DAT [9]. The MDMA KI value to inhibit rat
SERT was determined to be 0.24 µM [15] and 2.6 µM [13].
The KI values for cocaine to inhibit rat DAT in vitro ranged
from 0.33 µM to 2.0 µM [9,17]. These differences are
likely due to different experimental procedures employed
by each laboratory, the different expression systems or tis-
sue preparation methods used, and different qualities of
drugs used.
Therefore, it is important to compare DAT, NET and SERT
in their responses to psychostimulants in the same cellu-
lar background, using a uniform protocol and drugs. One
of our earlier studies compared the cloned DAT, NET and
SERT transporters stably expressed in LLC-PK1 cells, but
the available transporter cDNAs were from different spe-
cies [10]. In another study, human clones of the DAT, NET
and SERT transporters were stably expressed in HEK293
cells and the uptake inhibition by selected drugs including
some psychostimulants were compared [14]. Several
other studies examined rat transporters using synapto-
somes prepared from rat brains [13,15,18,19]. So far,
there is no study focusing on the comparison of psychos-
timulant potencies among the mouse monoamine trans-
porters and how they compare to the human transporters.
With the ever wider use of genetically modified mouse
models in recent years, experimental data that compare
drug effects between human and mouse monoamine
transporters are becoming increasingly important.
In the present study, we compared the potencies of five
psychostimulant drugs in inhibiting human and mouse
monoamine transporters in the same background and
using the same procedure. The drugs examined were
cocaine, methylphenidate, amphetamine, methampheta-
mine, and MDMA. Our results provide new information
and confirm most of the published data while differ from
some of the previous results. This study, combined with
results from other studies, provides very useful informa-
tion about which neurotransmission pathways are likely
to be affected the most by each of the drugs, which gives
insight into primary mechanisms of drug actions.
Results and discussion
Transiently transfected cells are used to determine the KI
values for drugs inhibiting wild type and mutant
monoamine transporters in our laboratory and other lab-
oratories [20-26]. Fluctuations in transporter expressionBMC Pharmacology 2006, 6:6 http://www.biomedcentral.com/1471-2210/6/6
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Drug inhibition profiles of mouse and human monoamine transporters by psychostimulants Figure 1
Drug inhibition profiles of mouse and human monoamine transporters by psychostimulants. Intestine 407 cells 
were transfected with human or mouse DAT, SERT, or NET cDNAs. Twenty to 24 hours after transfection, cells were incu-
bated with [3H] labeled substrate in PBS/Mg/Ca buffer for 10 min in the absence or presence of increasing concentrations of a 
psychostimulant drug as indicated. Uptake was terminated by two successive washes with PBS/Mg/Ca. The amounts of [3H] 
labeled substrate accumulated in the cells were determined by scintillation counting. The uptake activities are presented as 
fractional activities relative to those in the absence of drugs. The experiments were performed in triplicates. Each data point is 
expressed as mean ± SEM. The five drugs tested are: A) Cocaine; B) Methylphenidate (Ritalin); C) Amphetamine; D) Metham-
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levels have little impact on KI measurement except when
expression levels are very low resulting in unacceptable
signal to noise ratio. In this study, human and mouse
DAT, NET, and SERT cDNAs were transiently expressed in
cultured Intestine 407 cells. Transport activities by the
transfected cells were measured in the presence of increas-
ing concentrations of drugs. The KI values were then deter-
mined. Five psychostimulant drugs were studied: cocaine,
methylphenidate, amphetamine, methamphetamine, and
MDMA. For each of these drugs, the transporters were
studied in the same experiments for more precise compar-
ison. Fig. 1 shows representative results for each of the 5
drugs. The results are summarized in Table 1 displaying
the average KI values from 4–7 experiments. The ratios of
highest KI values over the lowest were calculated to high-
light the differences. The results and conclusions from this
study were obtained using Intestine 407 cells, which may
not apply to other cell lines or in vivo systems.
Cocaine
Fig. 1A shows that cocaine inhibited DAT, SERT, and NET
from human or mouse within a narrow range of concen-
trations. The KI values were from 0.2 to 0.7 µM. Among
the human monoamine transporters, cocaine was a
slightly more potent inhibitor of hDAT (KI = 0.23 µm)
than hSERT (KI = 0.74 µm) with hNET in the middle (KI =
0.48 µm). The cocaine potencies that inhibit mouse trans-
porters were very similar to those for the human trans-
porters except that the KI for mDAT (0.49 µm) was about
twice the value for hDAT. Compared to earlier studies, our
KI value (0.23 µM) for hDAT was similar to the KI value
(0.278 µM) reported by Eshleman, et al. for hDAT stably
expressed in HEK293 cells [14] but 4 times the value (KI =
0.058 µM) reported by Giros, et al. for hDAT expressed in
mouse fibroblast Ltk-cells [27]. For both human and
mouse NET and SERT, our data indicated that NET is
slightly more sensitive to cocaine than SERT, while two
previous studies using rat synaptosomes or human trans-
porters expressed in cultured cells [14,15] suggest that
SERT is slightly more sensitive to cocaine than NET.
Despite the small differences, all studies show that
cocaine inhibits DAT, NET and SERT within a narrow con-
centration range, suggesting that modulation of all three
neurotransmitter systems are likely to contribute to the
biochemical and behavioural effects of cocaine.
Methylphenidate (Ritalin)
As shown in Fig. 1B and Table 1, methylphenidate was a
very potent inhibitor of hDAT and hNET (KI = 0.06 µM
and 0.10 µM), while it was not a potent inhibitor of
hSERT (KI = 132 µM). Therefore, hSERT is over 2000 fold
less sensitive to methylphenidate than hDAT. Compari-
son between the two species revealed that methylpheni-
date was 4-fold more potent to inhibit hDAT than mDAT,
while it had similar effects on NET or SERT from the two
species. Our data show trends similar to those previously
reported for human transporters expressed in HEK cells
[14] and for rat transporters studied with rat brain synap-
tosomes [13]. For instance, the methylphenidate KIvalues
determined by Eshleman et al are 0.19 µM for hDAT,
0.038 µM for hNET and 55 µM for hSERT [14]. The com-
mon conclusion from all these studies is that SERT is
much less sensitive to methylphenidate than DAT and
NET.
Methylphenidate is marketed as Ritalin and is prescribed
to treat ADHD particularly for children. This prescription
drug is also addictive and has been abused. It has been
reported that cocaine and methylphenidate accumulate in
the same regions in the human brain and have similar
effectiveness in blocking DAT in vitro and in vivo [28].
However, methylphenidate abuse by humans is much less
frequent than that for cocaine [29]. The major difference
between methylphenidate and cocaine is that SERT is not
significantly inhibited by methylphenidate with doses
that completely block DAT and NET while cocaine blocks
Table 1: Comparison of the KI values of 5 psychostimulants to inhibit human and mouse monoamine transporters.
Drug Cocaine Methylphenidate Amphetamine Methamphetamine MDMA
Human
hDAT 0.23 ± 0.03 0.06 ± 0.01 0.64 ± 0.14 0.46 ± 0.06 8.29 ± 1.67
hNET 0.48 ± 0.05 0.10 ± 0.01 0.07 ± 0.01 0.11 ± 0.01 1.19 ± 0.13
hSERT 0.74 ± 0.03 132.43 ± 10.71 38.46 ± 3.84 31.74 ± 2.40 2.41 ± 0.73
Ratio 1 3.2 2207 549 288 7.0
Mouse
mDAT 0.49 ± 0.04 2 0.26 ± 0.03 0.56 ± 0.11 0.47 ± 0.08 4.87 ± 0.65
mNET 0.46 ± 0.06 2 0.17 ± 0.03 0.12 ± 0.02 0.19 ± 0.05 1.75 ± 0.51
mSERT 0.73 ± 0.12 114.37 ± 7.61 23.82 ± 1.71 9.28 ± 0.86 0.64 ± 0.05
Ratio 1 1.6 672 199 49 7.6
The KI values (in µM) were determined as illustrated in Fig. 1. They are expressed as mean ± S.E.M. of four to seven experiments. 1 The ratios of 
highest KI values over the lowest are shown to highlight the differences. 2 The difference between these two KI values was not statistically significant 
(ANOVA post hoc Bonferroni test, p > 0.05); all other values were statistically different (ANOVA comparing the three transporters within the same 
species and for the same drug).BMC Pharmacology 2006, 6:6 http://www.biomedcentral.com/1471-2210/6/6
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all three transporters equally well. This difference likely
contributes to the different effects produced by the two
drugs. Another likely contributing factor is the different
pharmacokinetics for the two drugs with cocaine reaching
its site of action much more rapidly than methylpheni-
date.
Amphetamine and methamphetamine
Among human transporters, amphetamine was most
potent at inhibiting hNET (KI = 0.07 µM). Compared to
the amount of amphetamine required to inhibit hNET, 9-
fold and over 500-fold more amphetamine was required
to inhibit hDAT (KI = 0.64 µM) and hSERT (KI = 38 µM)
respectively. The potencies of methamphetamine (Fig.
1D) to inhibit human and mouse monoamine transport-
ers are similar to those of amphetamine (Fig. 1C). We
compared the human and mouse monoamine transport-
ers and found that the transporters from the two spices
responded to amphetamine and methamphetamine in a
similar fashion (Fig. 1C, 1D, and Table 1). Our results are
not the same as those from previous studies but show a
similar trend. In one study with rat synaptosomes, the
amphetamine KI values are 0.034 µM for rDAT, 0.039 µM
for rNET, and 3.8 µM for rSERT [15]. In another study
using cultured cells expressing human transporters, the
methamphetamine KI values are 0.082 µM for hDAT,
0.0013 µM for rNET, and 20.7 µM for hSERT. Therefore,
amphetamine and methamphetamine are at least 100-
fold less potent at inhibiting SERT than DAT or NET.
Amphetamine is a synthetic drug. While prescribed for
treating ADHD, amphetamine has also been frequently
diverted from prescription to recreational use. Metham-
phetamine is an amphetamine analogue which also has
some limited therapeutic uses, primarily in the treatment
of ADHD and obesity. In recent years, the abuse of meth-
amphetamine becomes an extremely serious and growing
problem. Amphetamine and its analogues are also sub-
strates of the monoamine transporters and the vesicular
monoamine transporter. They compete with and
exchange with monoamines at the plasma membrane
transporters and also at the vesicular monoamine trans-
porter, disrupting the reuptake process and causing the
release of monoamines [7,30]. Amphetamine induced
monoamine release is usually studied using animal brain
preparations which contain both the plasma membrane
and vesicular monoamine transporters. Cultured cells
expressing only plasma membrane transporters are usu-
ally used to measure the KI values of uptake inhibition
which reflect the apparent affinities of the drugs to each
transporter. The KI value includes the effect of ampheta-
mine induced substrate release and it is not exactly the
same as the dissociation constant KD, a true measurement
of drug affinity. In this study, we focused on comparing KI
values of the transporters and did not study drug induced
releases. The results show that amphetamine and meth-
amphetamine are most potent in inhibiting NET and
much less potent in inhibiting SERT in both human and
mouse.
MDMA
As its name indicated, 3,4-methylenedioxymethampheta-
mine is a compound with a methylenedioxy group added
to methamphetamine. The chemical modification sub-
stantially increases MDMA's potency to inhibit SERT
while reducing its potencies to inhibit DAT and NET com-
pared to methamphetamine. This brings the KI values for
all three monoamine transporters to a close range (7-
fold). In mouse, the order of potencies for MDMA was
SERT (KI = 0.64 µM), NET (KI = 1.75 µM), and DAT (KI =
4.87 µM). For human transporters, the order was NET (KI
= 1.19 µM), SERT (KI = 2.41 µM), and DAT (KI = 8.29 µM).
In previous studies, Rothman, et al. has reported that
among the rat transporters, MDMA is most potent at
inhibiting rSERT (KI = 0.238 µM), followed by rNET (KI =
0.462  µM) and rDAT (KI = 1.572 µM) [15]. However,
another study has reported that MDMA is more potent at
inhibiting rDAT (KI = 1.53 µM) than rSERT (KI = 2.6 µM)
[13]. Our data for the mouse and human transporters are
similar to the results by Rothman et al for rat transporters
[15]. Our results indicate that MDMA is more potent in
inhibiting SERT than DAT, which is in contrary to the
other amphetamine derivatives.
Conclusion
There are significant discrepancies in previous studies on
the potencies of psychostimulant drugs at monoamine
transporters, likely due to differences in experimental set-
ups, expression systems, tissue preparations, and/or drug
qualities. In this study, we compared the potencies of five
commonly abused psychostimulants at the human and
mouse DAT, SERT and NET in the same cellular back-
ground. Cocaine blocked the 3 monoamine transporters
at similar concentrations (KI = 0.2–0.7 µM). In compari-
son, methylphenidate inhibited DAT and NET around 0.1
µM, while inhibited SERT at 1000 fold higher concentra-
tion (around 100 µM). Amphetamine and methampheta-
mine were most potent for NET (KI around 0.1 µM), less
potent for DAT (KI around 0.5 µM), and much less potent
for SERT (KI between10 to 40 µM). In contrast, MDMA,
another amphetamine derivative, exhibited higher
potency at SERT than at DAT. The human and mouse
transporters were similar in their sensitivities to each of
the tested drugs (KI values within 4 folds). The relative
potencies of a drug in inhibiting DAT, NET and SERT sug-
gest the neurotransmitter systems that are disrupted the
most and thus the primary mechanism of drug action.BMC Pharmacology 2006, 6:6 http://www.biomedcentral.com/1471-2210/6/6
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Methods
Materials
Cocaine, D-amphetamine, and methylphenidate were
kindly provided by National Institute on Drug Abuse
through its Drug Supply Program. D-methamphetamine
and MDMA were purchased from Sigma (St Louis, MO).
[3H]-labelled dopamine (23.5 Ci/mmole) and [3H]-
labelled serotonin (27.1 Ci/mmole) were purchased from
PerkinElmer Life and Analytical Sciences (Boston, MA).
The human dopamine, norepinephrine, and serotonin
transporter cDNAs used in the experiments were
described previously [10,31,32]. The cloning of mouse
DAT cDNA was reported in an earlier publication [33].
The mouse NET and SERT cDNAs were amplified with
nested PCR using mouse brain cDNAs as the template.
The forward primers for mNET are: mNETf1 (CAGCCG-
CACCCATGCTTCT) and mNETf2 (AAAAGGTACCAC-
CATGCTTCTGGCGCGAAT); the reverse primers are
mNETr1 (TCCTCCACATTGCCAGGTTCAGA) and
mNETr2 (AAAATCTAGAGGTTCAGAT-
GGCCAGCCAGTG). The forward primers for mSERT are
mSTf1 (AGCTAGTCAGGGTCCTTGGCAGATG) and
mSTf2 (ATATCCATGGAGACCACACCTTTGAATTCTC),
and reverse primers are mSTr1 (TGGGGCTTTTCAGAGAT-
GAGGAGTC) and mSTr2 (TAATCTCGAGCCATGTC-
CTCTCCCTCAGTGTGTTAC). Restriction enzyme sites
were incorporated in the primers for insertion into plas-
mid vectors. Oligonucleotide primers were synthesized by
commercial DNA synthesis services. The correct sequences
of mNET and mSERT were confirmed by sequence deter-
mination.
Transient expression of the transporter cDNAs
The transporter cDNAs were subcloned into the bluescript
vector SKII+ (Strategene, La Holla, CA) which has a T7
promoter. The cDNAs were transiently expressed in mon-
key Intestine 407 cells (CCL-6, American Type Culture
Collection, Rockville, MD) and characterized as described
[21,33]. Briefly, cells were plated in 96-well plates, trans-
fected with plasmid DNA using Lipofectin (Invitrogen Life
Technologies, Carlsbad, CA) according to manufacturer's
instruction, and infected with a recombinant vaccinia
virus VTF-7 which carries the T7 polymerase gene [34].
Transport measurement and drug inhibition
After 20- to 24-hour incubation, the transfected cells were
washed once with PBS/Ca/Mg (phosphate buffered saline
solution supplemented with 1 mM MgCl2, 0.1 mM
CaCl2), and then incubated for 10 minutes at 20°C in the
same buffer containing 50 nM [3H]-labelled substrate, 50
µM L-ascorbic acid (to protect the substrates from being
oxidized), and different concentrations of the tested drugs
(as described in Results or in each figure legend). At the
end of the incubation, cells were washed 2 times with
PBS/Ca/Mg, and then dissolved in 0.1 M NaOH. The
amount of accumulated [3H]-labelled substrate in the
cells were determined by counting in scintillation fluid
(MicroScint-20, PerkinElmer Life Sciences, Boston, MA)
using a Packard TopCount, a microplate scintillation and
luminescence counter. All experiments were performed in
triplicates.
Data analysis
The IC50 values were determined by nonlinear regression
of experimental data for each experiment according to a
hyperbolic model using the computer program Origin
(MicroCal Software, Northampton, MA). The KI values
were then calculated from the IC50 values using the equa-
tion KI = IC50/(1 + [S]/KM). Data are presented as arithme-
tic mean ± SEM of four to seven independent experiments.
ANOVA was used to determine statistical significance.
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